Prof. Anna Giuliano, Moffit Cancer Center, Tampa, Florida, USA Prof. Sharon Lewin, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia Prof. Giuseppe Pantaleo
First vaccine to target dendritic cells, key activators of the immune system Novel delivery of the HIV envelope protein potentially critical to future vaccine strategies Safe and able
CD40HVac, a therapeutic vaccine candidate in immuno-oncology targeting dendritic cells LinKinVax, a clinical-stage biotechnology company specialized in innovative protein-based vaccines, and Gustave
Alexandra Powell-Smith, PhD, Head of regulatory affairs Hasnae Niang, Head of Quality Thierry Menguy, PhD, Head of CMC activities Valérie Bouchara, PhD, Head of clinical operations
An international expert in the financing and growth of high tech businesses LinKinVax, a clinical-stage biotechnology company specializing in the treatment of infectious diseases and certain forms